Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

Breast Neoplasms

Interventions

DRUG

AVE1642

AVE1642 is administered intravenously at the dose of 8 mg/kg.

DRUG

Fulvestrant

Fulvestrant is administered as a slow intramuscular injection (just before the AVE1642 infusion when given in combination).

Trial Locations (3)

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, Barcelona